21 results
8-K
EX-99.1
UNCY
Unicycive Therapeutics Inc
14 Nov 23
Unicycive Announces Third Quarter 2023 Financial Results and Provides Business Update
4:42pm
development and corporate leadership experience. We also remain very active within the the medical community with a booth at Kidney Week and positive results … of Sara Kenkare-Mitra, PhD, adding decades of drug development and corporate leadership experience. Dr. Kenkare-Mitra brings Unicycive expertise spanning
8-K
EX-99.1
UNCY
Unicycive Therapeutics Inc
6 Sep 23
Unicycive Therapeutics Strengthens Board of Directors with Appointment of Sara Kenkare-Mitra, PhD
9:16am
believe Sara’s leadership and experience in drug development spanning more than 25 years will significantly help bolster Unicycive’s future growth … .
“We are thrilled to welcome Dr. Kenkare-Mitra to our Board of Directors and know that her extensive drug development and corporate leadership experience
PRE 14A
a1pg4y02q2707gz
18 Apr 23
Preliminary proxy
5:25pm
DEF 14A
tv8 77yjluty5mzm7
19 Apr 22
Definitive proxy
4:00pm
10-K
rzynv
31 Mar 22
Annual report
6:18am
10-Q
hdvurhf5 8ihyh8cm7
16 Aug 21
Quarterly report
6:06am
424B4
zb04 imlb5zu
14 Jul 21
Prospectus supplement with pricing info
1:59pm
S-1/A
vx41jobw5hm
7 Jun 21
IPO registration (amended)
7:01am
S-1
4znwa3x
21 May 21
IPO registration
4:07pm
DRS/A
hw5blm6tw 1inup
29 Apr 21
Draft registration statement (amended)
12:00am
DRS/A
f6umxmyzz0
18 Feb 21
Draft registration statement (amended)
12:00am
DRS/A
s04 oc5zl5qdfkop
2 Nov 20
Draft registration statement (amended)
12:00am